| COVID-19 |
1 |
1 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.95 |
| Acute Respiratory Distress Syndrome |
0 |
0.31 |
| Severe Acute Respiratory Syndrome |
0 |
0.31 |
| Biologic Therapy |
0 |
0.16 |
| Blood |
0 |
0.16 |
| Cancer |
0 |
0.12 |
| Otolaryngology |
0 |
0.12 |
| Acute Disease |
0 |
0.08 |
| Biomarker |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.08 |
| Plasma |
0 |
0.08 |
| T-Lymphocyte |
0 |
0.08 |
| Systemic Lupus Erythematosus |
0 |
0.05 |
| Adverse Effects |
0 |
0.04 |
| Anosmia |
0 |
0.04 |
| Antiviral Agents |
0 |
0.04 |
| Cytomegalovirus |
0 |
0.04 |
| Dyspnea |
0 |
0.04 |
| Electronic Medical Record |
0 |
0.04 |
| Epstein-Barr Virus |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Fatigue |
0 |
0.04 |
| Immunobiology |
0 |
0.04 |
| Immunoglobulin G (IgG) |
0 |
0.04 |
| Immunotherapy |
0 |
0.04 |
| Lupus |
0 |
0.04 |
| Match |
0 |
0.04 |
| Medical Innovations |
0 |
0.04 |
| Medical Life |
0 |
0.04 |
| Memory |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Proteomics |
0 |
0.04 |
| Type 2 Diabetes Mellitus |
0 |
0.04 |
| Viral Load |
0 |
0.04 |
| Washington |
0 |
0.04 |